Evidence map›Paper›PMID 35664677›Full record

ArticleFrontiers in molecular biosciences2022

A Resource to Infer Molecular Paths Linking Cancer Mutations to Perturbation of Cell Metabolism.

Marta Iannuccelli, Prisca Lo Surdo, Luana Licata, Luisa Castagnoli, Gianni Cesareni, Livia Perfetto

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Marta IannuccelliDepartment of Biology, University of Rome Tor Vergata, Rome, Italy.
Prisca Lo SurdoDepartment of Biology, University of Rome Tor Vergata, Rome, Italy.
Luana LicataDepartment of Biology, University of Rome Tor Vergata, Rome, Italy.
Luisa CastagnoliDepartment of Biology, University of Rome Tor Vergata, Rome, Italy.
Gianni CesareniDepartment of Biology, University of Rome Tor Vergata, Rome, Italy.
Livia PerfettoDepartment of Biology, University of Rome Tor Vergata, Rome, Italy.
University of Rome Tor Vergata · ITHuman Technopole · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Some inherited or somatically-acquired gene variants are observed significantly more frequently in the genome of cancer cells. Although many of these cannot be confidently classified as driver mutations, they may contribute to shaping a cell environment that favours cancer onset and development. Understanding how these gene variants causally affect cancer phenotypes may help developing strategies for reverting the disease phenotype. Here we focus on variants of genes whose products have the potential to modulate metabolism to support uncontrolled cell growth. Over recent months our team of expert curators has undertaken an effort to annotate in the database SIGNOR 1) metabolic pathways that are deregulated in cancer and 2) interactions connecting oncogenes and tumour suppressors to metabolic enzymes. In addition, we refined a recently developed graph analysis tool that permits users to infer causal paths leading from any human gene to modulation of metabolic pathways. The tool grounds on a human signed and directed network that connects ∼8400 biological entities such as proteins and protein complexes via causal relationships. The network, which is based on more than 30,000 published causal links, can be downloaded from the SIGNOR website. In addition, as SIGNOR stores information on drugs or other chemicals targeting the activity of many of the genes in the network, the identification of likely functional paths offers a rational framework for exploring new therapeutic strategies that revert the disease phenotype.

Indexed as

cancercausal interactionmetabolic pathwaynetworkrate limiting enzymeSIGNOR

Identifiers

PMID35664677
PMCPMC9158333
OpenAlexW4280600039

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.